Search Results for: biotechnolog

A new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship

A new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship, including case study of #OncoArendi Therapeutics authored by Marcin Szumowski A new series of

Read more

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will

Read more

Molecure has submitted a new application for approval to conduct a Phase II clinical trial for clinical candidate OATD-01 in the countries of the European Union and Norway

Molecure has resubmitted an application for approval to conduct a Phase II clinical trial for OATD-01 in Denmark, France, Greece, Germany and Norway. The company has proposed Denmark as the rapporteur Member State for the application

Read more

Molecure invites to the R&D Day – an online scientific and educational meeting on February 6, 2024

Warsaw, Poland – 29th January 2024 – Molecure S.A. (WSE ticker: MOC) a biotechnology company discovering and developing drugs to the clinical stage, utilizes world-class expertise in medicinal chemistry and biology to search for and develop

Read more

Molecure’s success in development of the mRNA discovery platform

- Molecure confirms that small molecules designed to target mRNA inhibit translation of the encoded protein relevant in cancer - Proof-of-Concept has been demonstrated in a cell assay - Reaching the PoC stage for the first

Read more

Molecure Announces Third Quarter 2023 Financial Results and Pipeline Highlights

U.S. Food and Drug Administration (FDA) approval to conduct a Phase II clinical trial for novel chitinase inhibitor OATD-01 in pulmonary sarcoidosis with first patient expected to be dosed in fourth quarter of 2023 Continued enrollment

Read more

Molecure Announces First Half 2023 Results – Significant Financial and Operating Momentum

Molecure strategy update for 2023-2025 based on the development of a diversified portfolio of innovative research projects with the potential for breakthrough therapies for incurable diseases Completed successful Secondary Public Offering (SPO) of gross proceeds of

Read more

Molecure submits application to the European Medicines Agency (EMA) to initiate a phase II clinical trial in the European Union and Norway to investigate OATD-01 for the treatment of pulmonary sarcoidosis

OATD-01 is a first-in-class inhibitor of chitotriosidase 1 (CHIT1) with disease-modifying potential in sarcoidosis and other interstitial lung diseases EMA approval will enable clinical trials to be conducted in centers in the European Union, including several

Read more

The U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch

Molecure can proceed with clinical trials in the U.S.A – Phase II proof-of-concept study will be the first to treat patients suffering from pulmonary sarcoidosis with OATD-01 In the coming weeks Molecure will also seek the

Read more
This site is registered on wpml.org as a development site.